Previous Close | 25.09 |
Open | 24.22 |
Bid | 23.79 x 600 |
Ask | 23.86 x 300 |
Day's Range | 23.35 - 24.95 |
52 Week Range | 4.82 - 27.66 |
Volume | |
Avg. Volume | 1,159,329 |
Market Cap | 1.9B |
Beta (5Y Monthly) | 0.77 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.91 |
Earnings Date | May 07, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 46.71 |
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on April 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 37,500 shares of its common stock and 18,750 restricted stock units ("RSUs") to three (3) new non-executive employees under the Avidity Biosci
President and CEO Sarah Boyce of Avidity Biosciences Inc (NASDAQ:RNA) sold 28,000 shares of the company on April 2, 2024, according to a recent SEC filing.
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conferences: